Lionheart Health, Inc. and ElectroMedical Technologies have announced a collaborative partnership designed to dramatically improve wound healing techniques and patient outcomes. The joint venture combines Lionheart's patented bioelectric signaling software with ElectroMed's advanced device technology platform, targeting a critical healthcare challenge: preventing limb amputations.
The partnership emerges from promising pilot studies demonstrating remarkable success rates. In previous studies conducted across the United States, Czech Republic, and Mexico, over 90% of patients with non-healing wounds who were previously considered candidates for amputation successfully preserved their limbs.
The collaboration plans to launch comprehensive clinical studies exploring multiple treatment approaches, including bioelectric stimulation, enhanced protein regeneration techniques, membrane grafts, and advanced stem cell interventions. With approximately 185,000 amputations occurring annually in the United States, predominantly related to non-healing wounds, the joint venture aims to reduce this number by more than half within ten years.
Matthew Wolfson, CEO of ElectroMed Technologies, emphasized the transformative potential of their combined technologies, suggesting the partnership could revolutionize wound care for generations. The venture represents a significant advancement in medical technology, leveraging Lionheart's 500 patent claims related to bioelectric protein expressions and tissue regeneration.
The companies plan to expand access to their innovative wound healing protocols by establishing 124 certified clinics worldwide. Through a licensing model, they intend to make their advanced treatment technologies available to qualified medical providers, with the joint venture receiving a 7% gross sales royalty for each patient service.
